Global Diagnostics Partnering Terms and Agreements Deals Report/Directory 2015-2022
14 Jun 2022
DUBLIN, June 14, 2022 /PRNewswire/ -- The "Global Diagnostics Partnering Terms and Agreements 2015-2022" report has been added to
ResearchAndMarkets.com's offering.
The Global Diagnostics Partnering Terms and Agreements 2015-2022 report provides comprehensive access to available deals and contract documents for over 3,200 Diagnostics deals.
The report provides a detailed understanding and analysis of how and why companies enter Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Diagnostics agreements announced in the life sciences since 2015.
The report takes the reader through a comprehensive review Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Diagnostics partnering deals.
The report presents financial deal term values for Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Diagnostics partnering field; both the leading deal values and most active Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 3,200 online deal records of actual Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
A comprehensive series of appendices is provided organized by Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Diagnostics partnering and dealmaking since 2015.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Diagnostics technologies and products.
This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:
Companion Diagnostics
Imaging
CT
Molecular and nuclear
MRI
X-ray
PET
Angiography
Fluroscopy
In vitro diagnostics
Molecular diagnostics
Prognostics
Theranostics
Key benefits
Global Diagnostics Partnering Terms and Agreements 2015-2022 provides the reader with the following key benefits:
In-depth understanding of Diagnostics deal trends since 2015
Access to headline, upfront, milestone and royalty data
Detailed access to actual Diagnostics contracts entered into by leading biopharma companies
Identify most active Diagnostics dealmakers since 2015
Insight into terms included in a Diagnostics partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
In Global Diagnostics Partnering Terms and Agreements 2015-2022, the available deals are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Diagnostics dealmaking
2.1. Introduction
2.2. Diagnostics partnering over the years
2.3. Most active Diagnostics dealmakers
2.4. Diagnostics partnering by deal type
2.5. Diagnostics partnering by therapy area
2.6. Deal terms for Diagnostics partnering
2.6.1 Diagnostics partnering headline values
2.6.2 Diagnostics deal upfront payments
2.6.3 Diagnostics deal milestone payments
2.6.4 Diagnostics royalty rates
Chapter 3 - Leading Diagnostics deals
3.1. Introduction
3.2. Top Diagnostics deals by value
Chapter 4 - Most active Diagnostics dealmakers
4.1. Introduction
4.2. Most active Diagnostics dealmakers
4.3. Most active Diagnostics partnering company profiles
Chapter 5 - Diagnostics contracts dealmaking directory
5.1. Introduction
5.2. Diagnostics contracts dealmaking directory
Chapter 6 - Diagnostics dealmaking by technology type
Appendices
Appendix 1 - Diagnostics deals by company A-Z
Appendix 2 - Diagnostics deals by stage of development
Discovery
Phase III
Marketed
Appendix 3 - Diagnostics deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Supply
Technology transfer
Termination
Warranty
Appendix 4 - Diagnostics deals by therapy area
Appendix 5 -Deal type definitions
Appendix 6 - Further reading on dealmaking
Companies Mentioned
IBA
iCAD
Icon
IDS
IDx
Imbio
Imec
IPMD
IQ-AI
ITEL
Item
ITOCO
KEW
Kore
Lab21
Great Basin Scientific
Anpac Bio-Medical Science
AmCad BioMed
For more information about this report visit https://www.researchandmarkets.com/r/9t1v3g
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.